UnitedHealth Group (UNH) insider filing shows a small, non-cash award and details of the reporting person's holdings. On 09/23/2025 the filing reports acquisition of 50 shares as dividend equivalents on vested deferred stock units, recorded at a $0 price because they represent vested awards rather than open-market purchases. The form shows the reporting person holds 427,895.942 shares directly, plus 349.7439 shares indirectly in a 401(k) and 681,875 shares indirectly in trusts. Explanatory notes state certain trust-to-direct and direct-to-trust transfers occurred on August 14, 2025 and were exempt from reporting under Rule 16a-13.
Paul R. Garcia, a director of UnitedHealth Group Inc. (UNH), reported an internal acquisition on 09/23/2025 consisting of 11 common stock units recorded as acquired at $0 as dividend equivalents on vested deferred stock units. The filing shows 2,761 shares beneficially owned directly after the transaction and additional indirect holdings of 2,146 shares via a revocable trust plus 45 and 55 shares via two other trusts. The dividend equivalents vested immediately and carry the same terms as the underlying deferred stock units.
Timothy P. Flynn, a director of UnitedHealth Group Inc. (UNH), reported a Section 16 transaction dated 09/23/2025. The filing shows 61 shares of Common Stock were acquired as dividend equivalents on vested deferred stock units, with a reported price of $0. Following the transaction, Mr. Flynn beneficially owned 9,538 shares directly and 6,033 shares indirectly through a trust. The form was signed by an attorney-in-fact on 09/25/2025. The filing is a single-person Form 4 and lists Mr. Flynn's relationship to the issuer as a director.
Michele J. Hooper, a director of UnitedHealth Group (UNH), received 236 shares on 09/23/2025 as dividend equivalents tied to vested deferred stock units; the reporting indicates these dividend equivalents are immediately vested and carry the same terms as the underlying deferred stock units. After the transaction, Hooper beneficially owned 40,715 shares. The Form 4 was signed by an attorney-in-fact on 09/25/2025. No cash consideration was paid for the 236 shares, consistent with dividend-equivalent treatment.
Frederick W. McNabb III, a director of UnitedHealth Group Inc. (UNH), reported a transaction on Form 4 showing the acquisition of 49 shares of Common Stock on 09/23/2025 at no cash price. The filing explains these 49 shares represent dividend equivalents paid on vested deferred stock units, which are immediately vested and subject to the same terms as the underlying units. Following the transaction, Mr. McNabb beneficially owns 14,052 shares. The Form 4 was signed by an attorney-in-fact on 09/25/2025.
UnitedHealth Group (UNH) reporting person Charles D. Baker received 1,256 shares of common stock as dividend equivalents on vested deferred stock units. The shares were issued through an acquisition transaction coded A (dividend equivalents) on 09/23/2025 at no cash price ($0), and the ownership is held directly. The filing notes these dividend equivalents become immediately vested and carry the same terms as the underlying deferred stock units. The Form 4 was submitted by an attorney-in-fact on behalf of the reporting person.
John H. Noseworthy, M.D., a director of UnitedHealth Group Inc. (UNH), reported a non‑derivative acquisition on 09/23/2025. The filing shows 39 shares of Common Stock were acquired at a reported price of $0, described as dividend equivalents paid on vested deferred stock units that are immediately vested and subject to the same terms as the underlying deferred stock units. After the transaction, Dr. Noseworthy beneficially owned 6,432 shares of UNH. The Form 4 was signed by an attorney‑in‑fact on 09/25/2025.
Valerie C. Montgomery Rice M.D., a director of UnitedHealth Group Inc. (UNH), reported a non‑derivative acquisition of 40 shares of common stock on 09/23/2025. The shares were recorded as dividend equivalents on vested deferred stock units and carried a $0 price; the filing shows 6,627 shares owned after the transaction. The dividend equivalents are immediately vested and subject to the same terms as the underlying deferred stock units. The Form 4 was signed by attorney‑in‑fact Faraz A. Choudhry on 09/25/2025.
Erin L. McSweeney, Executive Vice President and Chief People Officer of UnitedHealth Group (UNH), reported a non‑cash acquisition on 09/23/2025 consisting of 36.837 shares of common stock recognized as dividend equivalents on outstanding restricted stock units. The reported price is $0 because these shares represent dividend equivalents rather than a market purchase. Following this issuance, McSweeney beneficially owns 11,154.072 shares. The filing notes the dividend equivalents follow the same vesting terms as the underlying restricted stock units and are forfeitable if those units do not vest.
Christopher R. Zaetta, EVP & Chief Legal Officer of UnitedHealth Group (UNH), received 42.53 dividend-equivalent shares on 09/23/2025 that were paid on outstanding restricted stock units and are subject to the same vesting and forfeiture terms as the underlying RSUs. The transaction was reported on a Form 4 executed by an attorney-in-fact on 09/25/2025. The reported shares were issued at a $0 price as dividend equivalents and increase the reporting person’s beneficial ownership to 10,283.276 shares following the transaction.